Smith & Nephew SNATS, Inc. $SNN Shares Acquired by Ashton Thomas Securities LLC

Key Points

• Ashton Thomas Securities LLC increased its stake in Smith & Nephew SNATS, Inc. by 43.1%, owning 55,402 shares, valued at approximately $1.57 million following the purchase of an additional 16,692 shares in Q1.
• Several other institutional investors have made significant adjustments to their positions in Smith & Nephew, including Bessemer Group Inc., which raised its stake by 3,471.4%, bringing total institutional ownership to 25.64% of the company's stock.
• Smith & Nephew recently declared a semi-annual dividend of $0.285 per share with a yield of 210.0%, while analysts maintain a consensus rating of "Hold" with a target price of $36.00.

Ashton Thomas Securities LLC increased its holdings in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN - Free Report) by 43.1% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 55,402 shares of the medical equipment provider's stock after purchasing an additional 16,692 shares during the quarter. Ashton Thomas Securities LLC's holdings in Smith & Nephew SNATS were worth $1,572,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Bessemer Group Inc. increased its position in shares of Smith & Nephew SNATS by 3,471.4% during the 1st quarter. Bessemer Group Inc. now owns 1,750 shares of the medical equipment provider's stock worth $49,000 after purchasing an additional 1,701 shares during the last quarter. Sequoia Financial Advisors LLC acquired a new stake in shares of Smith & Nephew SNATS during the 1st quarter worth about $211,000. GAMMA Investing LLC increased its position in shares of Smith & Nephew SNATS by 22.4% during the 1st quarter. GAMMA Investing LLC now owns 3,641 shares of the medical equipment provider's stock worth $103,000 after purchasing an additional 666 shares during the last quarter. BNP Paribas Financial Markets acquired a new stake in shares of Smith & Nephew SNATS during the 4th quarter worth about $435,000. Finally, Barclays PLC acquired a new stake in shares of Smith & Nephew SNATS during the 4th quarter worth about $431,000. 25.64% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. Wall Street Zen raised Smith & Nephew SNATS from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 30th. Canaccord Genuity Group increased their price target on shares of Smith & Nephew SNATS from $28.00 to $36.00 and gave the stock a "hold" rating in a research report on Monday, August 18th. Six research analysts have rated the stock with a Hold rating, Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average price target of $36.00.

Smith & Nephew SNATS Stock Up 1.2%

Shares of NYSE SNN traded up $0.45 during midday trading on Friday, hitting $38.09. The company's stock had a trading volume of 1,215,377 shares, compared to its average volume of 589,653. The business's fifty day simple moving average is $33.57 and its two-hundred day simple moving average is $30.04. The company has a debt-to-equity ratio of 0.60, a current ratio of 3.00 and a quick ratio of 1.40. Smith & Nephew SNATS, Inc. has a 1 year low of $23.69 and a 1 year high of $38.41. The firm has a market capitalization of $16.68 billion, a price-to-earnings ratio of 17.63, a price-to-earnings-growth ratio of 1.04 and a beta of 0.71.

Smith & Nephew SNATS Cuts Dividend

The business also recently disclosed a semi-annual dividend, which will be paid on Friday, November 7th. Stockholders of record on Friday, October 3rd will be given a dividend of $0.285 per share. The ex-dividend date of this dividend is Friday, October 3rd. This represents a dividend yield of 210.0%. Smith & Nephew SNATS's payout ratio is currently 41.20%.

Smith & Nephew SNATS Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.